tiprankstipranks
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
US Market
SRPT
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (SRPT) Stock News & Sentiment

4,060 Followers
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
Premium
Ratings
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
19d ago
SRPT
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
Premium
Ratings
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
19d ago
SRPT
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
Premium
Weekend Updates
Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
1M ago
WBD
AXON
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
Premium
Company Announcements
Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
1M ago
SRPT
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
Premium
Company Announcements
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
1M ago
SRPT
Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
Premium
Ratings
Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
2M ago
SRPT
Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
Premium
Ratings
Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
2M ago
SRPT
More SRPT News >

SRPT News on the Web

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
TipRanks News
Neutral
Evercore ISI Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)
TipRanks News
Bearish
Why Sarepta Therapeutics Stock Is Sinking Today
TipRanks News
Bearish
Sarepta price target raised to $19 from $18 at RBC Capital
TipRanks News
Neutral
Why Sarepta Therapeutics Stock Is Suddenly Surging
TipRanks News
Bullish
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
TipRanks News
Neutral
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
Zacks
Bearish
Why Sarepta Therapeutics Stock Is Sinking Again
TipRanks News
Bearish

News Score - Last 7 Days

Very Negative
SRPT
Sector Average
Media Buzz
This Week3 articles
Weekly Average11.5 articles
News Sentiment
This Week0%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SRPT’s Media Buzz Sentiment?
3 articles about SRPT were published this week. In an average week, 11.5 articles are published.
    What is SRPT’s weekly average amount of articles?
    In an average week, 11.5 articles about SRPT are published.
      What is SRPT’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      TXTMProText Mobility
      STAAStaar Surgical
      ALLOAllogene Therapeutics
      REPLReplimune Group
      IVVDInvivyd
      Showing the stocks with the most bullish news sentiment over the past week